T1	Post-eligibility 0 74	The subject must be willingly and able to provide written informed consent
T2	Value 80 104	19 years of age or older
T3	Person 76 79	Age
R1	Has_value Arg1:T3 Arg2:T2	
T4	Non-representable 105 137	(The age of consent in Nebraska)
T5	Negation 153 158	naïve
T6	Procedure 143 152	treatment
T7	Condition 139 142	HCV
R2	Has_negation Arg1:T6 Arg2:T5	
R3	AND Arg1:T6 Arg2:T7	
T9	Drug 199 215	Interferon (IFN)
T8	Drug 217 220	RBV
T10	Non-representable 225 302	other FDA approved or experimental HCV-specific direct-acting antiviral agent
*	OR T9 T8
T11	Negation 174 176	no
T12	Temporal 177 182	prior
T13	Scope 199 220	Interferon (IFN), RBV
R4	Has_temporal Arg1:T13 Arg2:T12	
R5	Has_negation Arg1:T13 Arg2:T11	
T14	Scope 139 158	HCV treatment-naïve
T15	Scope 174 302	no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent
R6	Subsumes Arg1:T14 Arg2:T15	
T16	Measurement 304 317	HCV RNA level
T17	Temporal 318 368	at most 6 months prior to the Baseline/Day 1 visit
R7	Has_temporal Arg1:T16 Arg2:T17	
T18	Reference_point 344 368	the Baseline/Day 1 visit
R8	Has_index Arg1:T17 Arg2:T18	
T19	Measurement 371 385	HCV genotyping
T20	Value 386 408	1a, 1b, or mixed 1a/ab
R9	Has_value Arg1:T19 Arg2:T20	
T21	Non-representable 410 487	Any non-definitive results will exclude the subject from study participation.
T22	Condition 489 503	Alcohol misuse
T23	Measurement 522 577	Alcohol Use Disorders Identification Test (AUDIT) score
T24	Value 598 601	> 8
R10	Has_value Arg1:T23 Arg2:T24	
R11	Subsumes Arg1:T22 Arg2:T23	
T25	Procedure 664 676	liver biopsy
T26	Condition 685 694	cirrhosis
T27	Measurement 701 714	Metavir score
T28	Measurement 722 733	Ishak score
T29	Value 715 718	= 4
T30	Value 734 737	> 5
R12	Has_value Arg1:T27 Arg2:T29	
R13	Has_value Arg1:T28 Arg2:T30	
*	OR T27 T28
T31	Scope 701 737	Metavir score = 4 or Ishak score > 5
R14	Subsumes Arg1:T26 Arg2:T31	
R15	AND Arg1:T25 Arg2:T26	
T32	Procedure 740 749	Fibroscan
T33	Condition 758 767	cirrhosis
T34	Value 779 789	> 12.5 kPa
*	OR T33 T34
T35	Scope 758 789	cirrhosis or results > 12.5 kPa
R16	Has_scope Arg1:T32 Arg2:T35	
T36	Measurement 791 811	FIBRO Spect II index
T37	Measurement 850 878	platelet ration index (APRI)
T38	Value 882 885	> 2
R17	Has_value Arg1:T37 Arg2:T38	
T39	Temporal 886 902	during Screening
T40	Value 828 836	F3 or F4
T41	Value 844 847	AST
R18	Has_value Arg1:T36 Arg2:T40	
R19	Has_value Arg1:T36 Arg2:T41	
T42	Procedure 904 916	Liver biopsy
T43	Temporal 917 944	within 2 years of Screening
T44	Condition 964 973	cirrhosis
T45	Negation 953 960	absence
R20	Has_negation Arg1:T44 Arg2:T45	
R21	Has_temporal Arg1:T42 Arg2:T43	
R22	AND Arg1:T42 Arg2:T44	
T46	Procedure 975 984	Fibroscan
T47	Temporal 985 1017	within 6 months of Baseline/Day1
T48	Value 1035 1045	= 12.5 kPa
R23	Has_value Arg1:T46 Arg2:T48	
R24	Has_temporal Arg1:T46 Arg2:T47	
T49	Measurement 1047 1067	FIBRO Spect II Index
T50	Value 1084 1090	F0- F2
T51	Measurement 1095 1099	APRI
T52	Value 1103 1106	= 1
R25	Has_value Arg1:T51 Arg2:T52	
T53	Temporal 1107 1123	during Screening
R27	AND Arg1:T36 Arg2:T37	
R28	Has_value Arg1:T49 Arg2:T50	
R29	AND Arg1:T49 Arg2:T51	
R30	Has_temporal Arg1:T49 Arg2:T53	
R26	Has_temporal Arg1:T36 Arg2:T39	
T54	Procedure 1125 1138	Liver imaging
T55	Temporal 1139 1172	within 6 months of Baseline/Day 1
T56	Condition 1184 1213	hepatocellular carcinoma HCC)
R31	Has_temporal Arg1:T54 Arg2:T55	
T57	Negation 1176 1183	exclude
R32	Has_negation Arg1:T56 Arg2:T57	
R33	AND Arg1:T54 Arg2:T56	
T58	Measurement 1227 1230	ALT
T59	Measurement 1271 1274	AST
T60	Value 1231 1269	< 10 x the upper limit of normal (ULN)
T61	Value 1275 1285	< 10 x ULN
R34	Has_value Arg1:T58 Arg2:T60	
R35	Has_value Arg1:T59 Arg2:T61	
T62	Measurement 1287 1303	Direct bilirubin
T63	Value 1304 1315	< 2.0 x ULN
T64	Measurement 1317 1326	Platelets
T65	Value 1327 1335	> 50,000
R36	Has_value Arg1:T64 Arg2:T65	
R37	Has_value Arg1:T62 Arg2:T63	
T66	Measurement 1337 1342	HbA1c
T67	Value 1343 1349	< 8.5%
R38	Has_value Arg1:T66 Arg2:T67	
T68	Measurement 1351 1378	Creatinine clearance (CLcr)
T69	Value 1379 1391	= 60 mL /min
R39	Has_value Arg1:T68 Arg2:T69	
T70	Qualifier 1414 1438	Cockcroft-Gault equation
R40	Has_qualifier Arg1:T68 Arg2:T70	
T71	Measurement 1440 1450	Hemoglobin
T72	Value 1451 1460	= 11 g/dL
T73	Person 1465 1471	female
T74	Value 1482 1491	= 12 g/dL
T75	Person 1496 1500	male
A1	Optional T73
A2	Optional T75
R41	Has_value Arg1:T75 Arg2:T74	
R42	Has_value Arg1:T73 Arg2:T72	
*	OR T75 T73
T76	Scope 1451 1500	= 11 g/dL for female subjects; = 12 g/dL for male
R43	Has_scope Arg1:T71 Arg2:T76	
T77	Measurement 1512 1519	Albumin
T78	Value 1520 1530	= 2.5 g/dL
R44	Has_value Arg1:T77 Arg2:T78	
T79	Measurement 1532 1535	INR
T80	Value 1536 1547	= 1.5 x ULN
R45	Has_value Arg1:T79 Arg2:T80	
T81	Condition 1573 1583	hemophilia
T82	Condition 1590 1638	stable on an anticoagulant regimen affecting INR
*	OR T81 T82
T83	Negation 1548 1554	unless
T84	Scope 1573 1638	hemophilia or is stable on an anticoagulant regimen affecting INR
R46	Has_negation Arg1:T84 Arg2:T83	
R47	Has_scope Arg1:T79 Arg2:T84	
T85	Non-query-able 1641 1748	Subject has not been treated with any investigational drug or device within 30 days of the screening visit.
